NCT02035046View on ClinicalTrials.gov

Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter

NACompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Heterozygous Carriers of Gitelman Syndrome
Interventions
PROCEDURE

Samplings of blood

PROCEDURE

Sampling of urine

PROCEDURE

Measure of the blood pressure

PROCEDURE

glycemia test

Trial Locations (5)

75020

Department of Functional Investigations. Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Paris

75908

Clinical Research Center. Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou., Paris

87042 Limoges cedex

Nephrology Department. Centre Hospitalier Universitaire, Hôpital Dupuytren, Limoges

69437 Lyon

Department of Functional Investigations. Hospices Civils de Lyon, Hôpital Edouard Herriot., Lyon

31059 TOULOUSE cedex 9

Department of Functional Investigations. Centre Hospitalier Universitaire, Hôpital de Rangueil., Toulouse

All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02035046 - Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter | Biotech Hunter | Biotech Hunter